BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Osteoarthritis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for osteoarthritis: 270 (144 sponsors; 27 newly posted in the last 180 days, 11 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 7.2, rank 85 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 10, Phase 2 26, Phase 3 31, Phase 4 2, N/A 199.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Eli Lilly and Company LLY | 4 | P3 2, P2 2 | 1 | 2 |
| Novo Nordisk A/S NVO | 2 | P3 2 | 0 | 0 |
| Pfizer PFE new entrant | 2 | P3 2 | 2 | 0 |
| Pacira Pharmaceuticals, Inc PCRX | 4 | P3 1, P2 1, P1 1, NA 1 | 0 | 1 |
| Genascence Corporation | 2 | P1 1, P3 1 | 1 | 0 |
| Kolon TissueGene, Inc. | 2 | P3 1, P2 1 | 0 | 0 |
| PharmaResearch Co.,Ltd | 2 | P3 1, NA 1 | 1 | 0 |
| R-Bio | 2 | P3 1, NA 1 | 0 | 1 |
| CELL Technologies Inc. | 1 | P3 1 | 0 | 0 |
| Cellcolabs Clinical SPV Limited | 1 | P3 1 | 0 | 0 |
| CellSeed Inc. | 1 | P3 1 | 0 | 0 |
| Doron Therapeutics Inc. | 1 | P3 1 | 0 | 0 |
| DuoGenic StemCells Corporation (DGSC) new entrant | 1 | P3 1 | 1 | 0 |
| Fujian Shengdi Pharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| GID BIO, Inc. | 1 | P3 1 | 0 | 0 |
| Hangzhou Sciwind Biosciences Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| IBSA Institut Biochimique SA new entrant | 1 | P3 1 | 1 | 0 |
| Lipogems International spa | 1 | P3 1 | 0 | 0 |
| Magellan Stem Cells | 1 | P3 1 | 0 | 0 |
| Medipost, Inc. | 1 | P3 1 | 0 | 0 |
| Nature Cell Co. Ltd. | 1 | P3 1 | 0 | 0 |
| Overseas Pharmaceuticals, Ltd. | 1 | P3 1 | 0 | 0 |
| Paradigm Biopharmaceuticals Ltd. | 1 | P3 1 | 0 | 0 |
| Paradigm Biopharmaceuticals USA (INC) | 1 | P3 1 | 0 | 0 |
| Saol Therapeutics Inc | 1 | P3 1 | 0 | 1 |
New-entrant sponsors: Pfizer, DuoGenic StemCells Corporation (DGSC), Fujian Shengdi Pharmaceutical Co., Ltd., Hangzhou Sciwind Biosciences Co., Ltd., IBSA Institut Biochimique SA.
Recently stopped trials
- NCT02711254 Moximed - terminated: Adequate data has been collected Phantom Knee System Clinical Trial
- NCT04729387 Novartis Pharmaceuticals - terminated: Sponsor Decision Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutati
- NCT05497206 Zimmer Biomet - terminated: The data needed for regulatory submissions based on the current pace of the study, will not be available in the foreseeable future. ROSA® Hip System THA PMCF
- NCT06034262 TBF Genie Tissulaire - terminated: Poor accrual rate Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis
- NCT04093739 Zimmer Biomet - withdrawn: Manufacturer decided not to proceed with study. MDR - G7 Neutral and G7 Freedom Constrained Neutral Acetabular Liners
- NCT03953846 Phoenix Kinetics - terminated: Active Implants Europe closed operations NUsurface Implant Registry
- NCT05454566 ICM Co. Ltd. - withdrawn: Sponsor decided not to proceed with this study in the US. A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.
- NCT02851992 Zimmer Biomet - terminated: Zimmer Biomet is prioritizing specific products within its portfolio and has chosen not to extend the CE mark for the GTS stem under MDR req A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem
- NCT05092646 Axolotl Biologix - terminated: This study was terminated by the Sponsor in December 2023 due to business considerations. Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis
- NCT03247023 Smith & Nephew, Inc. - terminated: Sponsor decision not related to safety Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement
- NCT05002959 Zimmer Biomet - terminated: Termination of PMCF study due to product discontinuation (commercial reasons) TESS V3 Modular Total Shoulder System PMCF
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | Nuwacell Biotechnologies Co., Ltd. | NCT06741098 A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA) | Knee Osteoarthritis | not yet recruiting | 162 |
| 2026-11-30 est. | P3 | Saol Therapeutics Inc | NCT07226258 Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | Osteoarthritis Knee Pain | active not recruiting | 150 |
| 2026-12 est. | P3 | Pacira Pharmaceuticals, Inc PCRX | NCT06269705 ZILRETTA in Subjects With Shoulder Osteoarthritis | Glenohumeral Osteoarthritis | active not recruiting | 150 |
| 2026-12 est. | P3 | Wuxi Cellular Biopharmaceutical Group Ltd. | NCT06570291 Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | Knee Osteoarthritis | recruiting | 520 |
| 2026-12-23 est. | P3 | R-Bio | NCT04427930 Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial | Knee Osteoarthritis | active not recruiting | 129 |
| 2026-12-31 est. | P2 | Sclnow Biotechnology Co., Ltd. | NCT03383081 The Safety/Efficacy of hUC Mesenchymal Stem Cells(19#iSCLife®-OA) Therapy for Patients With Osteoarthritis | Osteoarthritis, Knee | recruiting | 60 |
| 2026-12-31 est. | P3 | TRB Chemedica | NCT04318041 Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients | Knee Osteoarthritis | active not recruiting | 128 |
| 2027-02 est. | P2 | Enlivex Therapeutics Ltd. ENLV | NCT07580716 Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis | Primary Knee Osteoarthritis | recruiting | 182 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Pacira Pharmaceuticals, Inc PCRX | NCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Osteoarthritis (OA) of the Knee | recruiting | 135 |
| 2026-11 est. | P2 | KeyBioscience AG | NCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | Osteoarthritis in the Knee; Obesity | recruiting | 600 |
| 2026-11 est. | P2 | TBF Genie Tissulaire | NCT06038331 Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis | Osteoarthritis Hand | active not recruiting | 14 |
| 2026-08-31 | P2 | 4Moving Biotech | NCT07225829 A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis | Knee Osteoarthritis; Synovitis of Knee | completed | 130 |
| 2026-08 est. | P3 | CELL Technologies Inc. | NCT06216028 Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis | Knee Osteoarthritis; Musculoskeletal Diseases | not yet recruiting | 374 |
| 2026-08 est. | P2 | VivaTech International, Inc. | NCT02844764 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip | Osteoarthritis | recruiting | 4000 |
| 2026-08 est. | P2 | VivaTech International, Inc. | NCT02844751 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee | Osteoarthritis | recruiting | 4000 |
| 2026-08 est. | P2 | VivaTech International, Inc. | NCT02844738 Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder | Osteoarthritis | recruiting | 4000 |
| 2026-07-31 est. | P2 | Glaceum | NCT06845553 A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients | Knee Osteoarthritis (Knee OA) | recruiting | 60 |
| 2026-06-01 est. | P1/P2 | BioIntegrate | NCT04711304 Evaluation of Safety and Efficacy of Wharton's Jelly Compared to Hyaluronic Acid and Saline for Knee Osteoarthritis. | Osteoarthritis, Knee | unknown | 168 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "osteoarthritis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.